INS and type 1 diabetes mellitus: In the recently FDA-approved donor-derived pancreatic islet cell therapy for T1D, known as Lantidra or donislecel (manufactured by CellTrans Inc.), the therapy is indicated for adults with T1D where exogenous administration of insulin is insufficient to maintain the HbA1c target and who experience hypoglycemia unawareness (26, 27).